The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.

Including the name of the #1 company to buy.

C. Noel Bairey Merz net worth and biography

C. Bairey Merz Biography and Net Worth

Director of iRhythm Technologies

C. Noel Bairey Merz, M.D. has served as a Director of iRhythm since April 2018. Dr. Bairey Merz has been the Medical Director of the Preventive and Rehabilitative Center at the Cedars-Sinai Medical Center in Los Angeles, California, since 1991. She also has been the Medical Director and Endowed Chair of the Barbra Streisand Women’s Heart Center at the Smidt Cedars-Sinai Heart Institute since 2001, and a Professor of Medicine at Cedars-Sinai Medical Center and the David Geffen School of Medicine at the University of California at Los Angeles. From 2005 to 2009, she served on the Scientific Advisory Board of CV Therapeutics, Inc. She also has extensive experience on nonprofit boards, councils, and guideline panels including the American College of Cardiology, the American Heart Association and the National Heart, Lung, and Blood Institute. Since 2016, Dr. Bairey Merz has been serving on multiple editorial boards including the Journal of the American College of Cardiology, Circulation, and European Heart Journal. Dr. Bairey Merz holds a B.A. (Honors) in Biological Sciences from the University of Chicago and an M.D. (Honors) from Harvard Medical School. She completed her training in Internal Medicine at the University of California, San Francisco, and Cardiology at Cedars-Sinai Medical Center.

What is C. Noel Bairey Merz's net worth?: The estimated net worth of C. Noel Bairey Merz is at least $441,735.93 as of September 12th, 2022. Dr. Bairey Merz owns 4,887 shares of iRhythm Technologies stock worth more than $441,736 as of December 22nd. This net worth evaluation does not reflect any other assets that Dr. Bairey Merz may own. Learn More about C. Noel Bairey Merz's net worth.
How do I contact C. Noel Bairey Merz?: The corporate mailing address for Dr. Bairey Merz and other iRhythm Technologies executives is 650 TOWNSEND STREET SUITE 500, San Francisco CA, 94103. iRhythm Technologies can also be reached via phone at (415) 632-5700 and via email at [email protected]. Learn More on C. Noel Bairey Merz's contact information.
Has C. Noel Bairey Merz been buying or selling shares of iRhythm Technologies?: C. Noel Bairey Merz has not been actively trading shares of iRhythm Technologies over the course of the past ninety days. Most recently, Merz Cathleen Noel Bairey sold 90 shares of the business's stock in a transaction on Monday, September 12th. The shares were sold at an average price of $159.77, for a transaction totalling $14,379.30. Following the completion of the sale, the director now directly owns 4,887 shares of the company's stock, valued at $780,795.99. Learn More on C. Noel Bairey Merz's trading history.
Who are iRhythm Technologies' active insiders?: iRhythm Technologies' insider roster includes C. Bairey Merz (Director), Quentin Blackford (CEO), Mark Day (EVP), Douglas Devine (CFO), Patrick Murphy (EVP), Chad Patterson (Chief Commercial Officer), Sumi Shrishrimal (EVP, Chief Risk Officer), Mervin Smith (EVP of Business Operations), Minang Turakhia (Chief Medical Officer, Chief Scientific Officer and EVP, Product Innovation), David Vort (EVP), and Daniel Wilson (EVP). Learn More on iRhythm Technologies' active insiders.
Are insiders buying or selling shares of iRhythm Technologies?: In the last year, iRhythm Technologies insiders bought shares 2 times. They purchased a total of 6,944 shares worth more than $521,860.64. In the last year, insiders at the sold shares 13 times. They sold a total of 69,024 shares worth more than $7,151,438.22. The most recent insider tranaction occured on December, 2nd when insider Patrick Michael Murphy sold 2,492 shares worth more than $214,037.88. Insiders at iRhythm Technologies own 0.7% of the company. Learn More about insider trades at iRhythm Technologies.
Information on this page was last updated on 12/2/2024.

C. Noel Bairey Merz Insider Trading History at iRhythm Technologies

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/12/2022	Sell	90	$159.77	$14,379.30	4,887
6/14/2022	Sell	500	$111.76	$55,880.00	4,977
6/13/2019	Sell	1,209	$76.40	$92,367.60	3,844

C. Noel Bairey Merz Buying and Selling Activity at iRhythm Technologies

iRhythm Technologies Company Overview

iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.

Today's Range

Now: $90.39

$85.29

$91.22

50 Day Range

MA: $80.38

$57.94

$91.45

2 Week Range

Now: $90.39

$55.92

$124.11

Volume

506,936 shs

Average Volume

465,130 shs

Market Capitalization

$2.83 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.26

Vladimir Lenin was right…

From Porter & Company | Ad